TED public contract notices · Public Contracts
Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130a Abs. 8 bzw. § 130c Absatz 1 des Fünften Sozialgesetzbuchs - Lytenava (Wirkstoff: Bevacizumab gamma), ATC S01LA08
Official identifier 402266-2025
IrelandContract
- Buyer
- DAK-Gesundheit
- Winner
- Outlook Therapeutics Limited
- Contract
- 1004803
- Lot
- LOT-0001
- Currency
- Official notice
- https://ted.europa.eu/en/notice/402266-2025
No linked company profile is available.